Longevity & Cellular
ARA-290
- Size
- 10mg
Specifications
ARA-290 Technical Profile
OVERVIEW
What Is ARA-290 (Cibinetide) Peptide?
ARA-290 (Cibinetide) is a synthetic undecapeptide engineered from the B-helix region of erythropoietin (EPO). Developed by Araim Pharmaceuticals, ARA-290 was designed to retain the tissue-protective signaling properties of EPO while eliminating its erythropoietic (red blood cell-stimulating) activity. This non-erythropoietic EPO-derived peptide selectively activates the innate repair receptor (IRR), making it a unique research tool for studying tissue protection and repair mechanisms without the hematological confounders associated with EPO itself.
Published research on ARA-290 peptide spans neuroprotection, metabolic neuropathy, sarcoidosis-associated neuropathy, and tissue repair models. The peptide's ability to activate the IRR, a heterodimeric complex of the EPO receptor (EPOR) and the beta common receptor (βcR/CD131), without triggering classical erythropoiesis has made cibinetide a valuable tool in laboratories investigating cytoprotective signaling pathways. ARA-290 research has progressed from preclinical models through multiple clinical research studies.
- 01
IRR-Selective Peptide
11-amino-acid EPO-derived peptide targeting the innate repair receptor without erythropoietic activity
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
ARA-290 Mechanism of Action in Research
The ARA-290 mechanism of action is distinct from classical erythropoietin signaling. While EPO activates homodimeric EPOR to stimulate erythropoiesis, ARA-290 selectively engages the innate repair receptor (IRR), triggering tissue-protective and anti-inflammatory signaling cascades. Published research has elucidated multiple downstream pathways activated by ARA-290's IRR engagement, providing insight into non-erythropoietic cytoprotective mechanisms.
Innate Repair Receptor (IRR) Activation
ARA-290 binds to the innate repair receptor, a heterodimer composed of EPOR and βcR (CD131). Research by Brines et al. (2008) demonstrated that this receptor complex is expressed on a wide variety of cell types including neurons, endothelial cells, and immune cells. Upon ARA-290 binding, the IRR activates JAK2/STAT5 signaling, PI3K/Akt pathways, and NF-κB modulation, collectively producing cytoprotective and anti-inflammatory effects in research models. Critically, ARA-290's affinity for the IRR is insufficient to activate the homodimeric EPOR, eliminating erythropoietic activity.
Anti-Inflammatory Signaling Pathways
Studies indicate that ARA-290 modulates inflammatory signaling through multiple mechanisms. Research published by Brines & Cerami (2012) in Molecular Medicine demonstrated that ARA-290 downregulates pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β while upregulating anti-inflammatory mediators. In preclinical models, ARA-290 has been observed to shift macrophage polarization from M1 (pro-inflammatory) toward M2 (anti-inflammatory/reparative) phenotypes, suggesting a role in resolution of inflammation and tissue repair signaling.
Neuroprotective Research Applications
ARA-290 research has demonstrated notable effects in neuroprotection models. Brines et al. (2008) published findings showing that ARA-290 activated neuroprotective pathways in dorsal root ganglia neurons. Subsequent clinical research by Heij et al. (2012) investigated ARA-290 in sarcoidosis-associated small fiber neuropathy models, documenting improvements in nerve fiber density measures, further establishing the peptide's relevance to neuroscience research. ---
COMPARISON
ARA-290 vs EPO: Research Compound Comparison
ARA-290
ARA-290 (Cibinetide) and erythropoietin (EPO) share a structural origin but differ fundamentally in receptor targeting, biological activity, and research applications. Understanding these differences is critical for researchers working with cytoprotective and erythropoietic signaling pathways.
EPO
ARA-290's selective IRR targeting without erythropoietic activity represents a significant advancement for researchers studying tissue-protective EPO signaling without hematological confounders. VivePeptides offers research grade ARA-290 for sale at ≥99% purity from our USA-based facility.
| Feature | ARA-290 (Cibinetide) | EPO (Erythropoietin) |
|---|---|---|
| Type | Synthetic undecapeptide | Glycoprotein hormone (165 aa) |
| Molecular Weight | 1257.43 Da | ~30,400 Da |
| CAS Number | 1208243-50-8 | 11096-26-7 |
| Target Receptor | Innate Repair Receptor (EPOR/βcR) | Homodimeric EPOR |
| Erythropoietic Activity | None | Primary function |
| Primary Research Focus | Neuroprotection, tissue repair, anti-inflammation | Erythropoiesis, red blood cell production |
| Safety Profile in Research | No hematological confounders | Thrombotic risk at high doses |
| Administration Route (Research) | Subcutaneous, intravenous | Subcutaneous, intravenous |
| Research Stage | Phase 2 clinical studies completed | FDA-approved therapeutic |
RESEARCH STUDIES
ARA-290 Research Applications & Published Studies
ARA-290 research includes both preclinical and clinical investigations, with published findings spanning multiple therapeutic research areas. The following areas represent the most actively investigated applications of ARA-290 peptide. All references are to research contexts only.
Neuropathy and Neuroprotection Research
The most extensively studied application of ARA-290 involves neuroprotection and neuropathy models. Brines et al. (2008) published foundational work in the Proceedings of the National Academy of Sciences demonstrating ARA-290's neuroprotective properties via IRR activation. Heij et al. (2012) subsequently published clinical research findings in Molecular Medicine showing that ARA-290 improved corneal nerve fiber measures in patients with sarcoidosis-associated small fiber neuropathy, representing a significant translational milestone.
Metabolic Neuropathy Research
Research has explored ARA-290 in metabolic neuropathy models. Brines et al. (2014) published findings in BMC Neurology from a randomized controlled study investigating ARA-290 in type 2 diabetes-associated neuropathy. The study documented effects on small nerve fiber measures and neuropathic symptoms, contributing to the understanding of IRR-mediated neuroprotection in metabolic disease research contexts.
Tissue Protection and Repair Studies
Preclinical ARA-290 research has examined the peptide's tissue-protective properties across multiple organ systems. Collino et al. (2013) published studies demonstrating ARA-290's effects in renal ischemia-reperfusion models. Additional research by Ahmet et al. (2011) investigated ARA-290 in cardiac injury models, observing cytoprotective effects consistent with IRR-mediated anti-apoptotic signaling, expanding the scope of ARA-290 research to cardiovascular biology.
QUALITY ASSURANCE
Quality & Testing Standards
VivePeptides maintains rigorous quality control for every batch of ARA-290 peptide. Our commitment to research-grade purity ensures that laboratories receive consistent, reliable compounds for their investigations.
HPLC & Mass Spectrometry
Every batch of ARA-290 undergoes high-performance liquid chromatography (HPLC) and mass spectrometry analysis to confirm identity, purity, and molecular weight.
Third-Party Verified
All VivePeptides ARA-290 is independently verified through third-party analytical laboratories based in the USA. Testing documentation is available for every lot.
≥99% Purity Standard
Our ARA-290 consistently meets or exceeds ≥99% purity as determined by HPLC analysis, ensuring research-grade quality for laboratory applications.
FAQ
Frequently Asked Questions About ARA-290
What is ARA-290 used for in research?
What purity is VivePeptides ARA-290?
How should ARA-290 be stored?
What is the difference between ARA-290 and EPO?
Is VivePeptides ARA-290 third-party tested?
BPC-157
Research grade gastric pentadecapeptide for tissue biology studies
TB-500
MOTS-c
Thymosin Beta-4 fragment for tissue repair and cell migration research
Mitochondrial-derived peptide for metabolic research
Selank
Nootropic peptide for neuropeptide research
Explore More Research Peptides
All Peptides → · BPC-157 · TB-500 · Vive GLP(S) · Semax · NAD+ · GHK-Cu · BAC Water
Add To Research Cart
ARA-290
99%+ purity · USA lab tested · secure shipping
You May Also Research
